Therapy of chronic lymphocytic leukaemia

Best Practice & Research. Clinical Haematology
Michael Hallek

Abstract

Rapid progress has been achieved recently in the management of chronic lymphocytic leukaemia (CLL). New insights into the molecular pathology of CLL have generated a plethora of biological markers that predict the prognosis and influence therapeutic decisions. Moreover, fludarabine, bendamustine and two monoclonal antibodies, alemtuzumab and rituximab, have been approved by European and/or American regulatory agencies. Additional monoclonal antibodies targeting CD20, CD23, CD37, CD38 or CD40, as well as drugs designed to interfere with proteins regulating the cell cycle, apoptotic machinery or leukaemic microenvironment (e.g., flavopiridol, oblimersen, ABT-263 or lenalidomide) are investigated in clinical trials. An increased experience with reduced-intensity allogeneic progenitor cell transplantation allows offering this option to physically fit patients. This review attempts to summarise the current use of these different modalities in CLL therapy.

References

Mar 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D Cheson
Jan 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S O'BrienM J Keating
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A OsterborgH Mellstedt
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M ExtermannL Balducci
Oct 3, 1998·Annals of Internal Medicine·E J AnaissieM J Keating
Dec 15, 2000·The New England Journal of Medicine·K R RaiC A Schiffer
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdI W Flinn
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M O'BrienM J Keating
Aug 25, 2001·Blood·D HuhnUNKNOWN German Chronic Lymphocytic Leukemia Study Group
Oct 6, 2001·Blood·M LeporrierUNKNOWN French Cooperative Group on Chronic Lymphocytic Leukemia
Aug 9, 2002·The New England Journal of Medicine·Stephan Stilgenbauer, Hartmut Döhner
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K R RaiL Brettman
Dec 11, 2002·British Journal of Haematology·Francesc BoschUNKNOWN GELCAB (Grup per l'Estudi dels Limfomes a Catalunya i Balears)
Apr 14, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Michael Hallek, Barbara F Eichhorst
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul MoretonPeter Hillmen
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William WierdaMichael Keating
Sep 8, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas ElterAndreas Engert
Jul 21, 2006·The Cochrane Database of Systematic Reviews·M SteurerR Greil
Nov 8, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Asher Chanan-KhanMyron S Czuczman
Nov 17, 2006·Leukemia·P DregerUNKNOWN Chronic Leukemia Working Party of the EBMT
Feb 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian W FlinnMartin S Tallman
Feb 14, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan O'BrienKanti R Rai
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John C ByrdSarah Harris
Nov 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HillmenJiri Mayer
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kenneth A FoonAhmad Tarhini
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephan StilgenbauerUNKNOWN German Chronic Lymphocytic Leukemia Study Group
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang U KnaufMarco Montillo

❮ Previous
Next ❯

Citations

May 18, 2011·JAAPA : Official Journal of the American Academy of Physician Assistants·Leslie Washburn
May 6, 2015·Seminars in Cancer Biology·Ramzi M MohammadAsfar S Azmi
Dec 3, 2011·Nucleosides, Nucleotides & Nucleic Acids·Paula X Fernández-CalottiMarçal Pastor-Anglada
Feb 9, 2018·International Journal of Molecular Sciences·Kez ClealDuncan Baird
Feb 23, 2013·The Australian and New Zealand Journal of Psychiatry·Stephen AllisonRichard Reed
Sep 7, 2014·Journal of Healthcare Engineering·S Hahn-GoldbergM W Carter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.